ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis

Significance The family of copper-dependent lysyl oxidase (LOX) enzymes contributes to tumor metastasis. In this study, we show that the ATP7A copper transporter is required to deliver copper to LOX family members. Deletion of ATP7A inhibited LOX activity in breast and lung cancer cell lines, resulting in a significant loss of tumor growth and metastatic potential of these cells in mice. Elevated expression of ATP7A was found to be associated with reduced survival of breast cancer patients. Our study suggests that blocking the function of ATP7A could be an approach to inhibiting LOX-dependent malignancies. Lysyl oxidase (LOX) and LOX-like (LOXL) proteins are copper-dependent metalloenzymes with well-documented roles in tumor metastasis and fibrotic diseases. The mechanism by which copper is delivered to these enzymes is poorly understood. In this study, we demonstrate that the copper transporter ATP7A is necessary for the activity of LOX and LOXL enzymes. Silencing of ATP7A inhibited LOX activity in the 4T1 mammary carcinoma cell line, resulting in a loss of LOX-dependent mechanisms of metastasis, including the phosphorylation of focal adhesion kinase and myeloid cell recruitment to the lungs, in an orthotopic mouse model of breast cancer. ATP7A silencing was also found to attenuate LOX activity and metastasis of Lewis lung carcinoma cells in mice. Meta-analysis of breast cancer patients found that high ATP7A expression was significantly correlated with reduced survival. Taken together, these results identify ATP7A as a therapeutic target for blocking LOX- and LOXL-dependent malignancies.

[1]  C. Counter,et al.  Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. , 2017, Cancer research.

[2]  Alberto Martin,et al.  Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. , 2017, Cancer research.

[3]  Craig A. Poland,et al.  Targeting lysyl oxidase reduces peritoneal fibrosis , 2017, PloS one.

[4]  Shan Zhu,et al.  A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance , 2017, Journal of Cancer.

[5]  D. Ribero,et al.  Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases , 2017, Cell reports.

[6]  Gianpiero di Leva,et al.  Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface , 2017, Nature Communications.

[7]  B. Stierstorfer,et al.  Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis , 2017, Scientific Reports.

[8]  Wolfgang,et al.  Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer , 2017, Oncotarget.

[9]  B. R. Seo,et al.  Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases , 2016, Clinical Cancer Research.

[10]  B. Győrffy,et al.  Potential options for managing LOX+ ER− breast cancer patients , 2016, Oncotarget.

[11]  M. Leverkus,et al.  Crystal Violet Assay for Determining Viability of Cultured Cells. , 2016, Cold Spring Harbor protocols.

[12]  J. Erler,et al.  Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis. , 2016, Cancer research.

[13]  S. Knapp,et al.  Abstract IA09: Copper is required for oncogenic BRAF signaling and tumorigenesis , 2014 .

[14]  I. Ng,et al.  Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma , 2014, Hepatology.

[15]  E. Brown,et al.  The Use of Second Harmonic Generation to Image the Extracellular Matrix During Tumor Progression , 2014, Intravital.

[16]  L. Papa,et al.  SOD1, an unexpected novel target for cancer therapy , 2014, Genes & cancer.

[17]  D. Hanahan,et al.  Bioavailable copper modulates oxidative phosphorylation and growth of tumors , 2013, Proceedings of the National Academy of Sciences.

[18]  J. Erler,et al.  Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK , 2013, Oncogene.

[19]  Guangmei Yan,et al.  Inactivation of lysyl oxidase by β-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells. , 2013, Oncology reports.

[20]  S. Howell,et al.  Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. , 2012, Biochemical pharmacology.

[21]  M. McKeage,et al.  Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. , 2012, Current cancer drug targets.

[22]  D. Thiele,et al.  Charting the travels of copper in eukaryotes from yeast to mammals. , 2012, Biochimica et biophysica acta.

[23]  Thomas R. Cox,et al.  The rationale for targeting the LOX family in cancer , 2012, Nature Reviews Cancer.

[24]  Y. Ho,et al.  Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway , 2012, Breast Cancer Research and Treatment.

[25]  D. Thiele,et al.  A Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase Signaling , 2012, Molecular and Cellular Biology.

[26]  Thomas R Cox,et al.  The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. , 2011, Journal of the National Cancer Institute.

[27]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[28]  C. Wai,et al.  Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.

[29]  Arantxa González,et al.  Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. , 2010, American journal of physiology. Heart and circulatory physiology.

[30]  Andrés J. García,et al.  Focal adhesion kinase‐dependent regulation of adhesive forces involves vinculin recruitment to focal adhesions , 2010, Biology of the cell.

[31]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[32]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[33]  G. Raposo,et al.  Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes , 2008, Nature.

[34]  B. Geiger,et al.  Vinculin controls focal adhesion formation by direct interactions with talin and actin , 2007, The Journal of cell biology.

[35]  D. Eide,et al.  A Histidine-rich Cluster Mediates the Ubiquitination and Degradation of the Human Zinc Transporter, hZIP4, and Protects against Zinc Cytotoxicity* , 2007, Journal of Biological Chemistry.

[36]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[37]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[38]  M. Hendrix,et al.  Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. , 2005, Cancer research.

[39]  S. Merajver,et al.  Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  H. Kagan,et al.  Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell , 2003, Journal of cellular biochemistry.

[41]  D. Gomez,et al.  The copper‐chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells , 2001, International journal of cancer.

[42]  J. Mercer,et al.  The Menkes copper transporter is required for the activation of tyrosinase. , 2000, Human molecular genetics.

[43]  S. Ostrand-Rosenberg,et al.  Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.

[44]  M. Luther,et al.  Involvement of pp60c-src with two major signaling pathways in human breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Froines,et al.  In vitro and in vivo inhibition of lysyl oxidase byaminopropionitriles , 1992 .

[46]  D. Danks,et al.  Reduced lysyl oxidase activity in skin fibroblasts from patients with Menkes' syndrome. , 1980, The Biochemical journal.

[47]  Abdul Kader Sagar,et al.  Second-harmonic generation imaging of cancer. , 2014, Methods in cell biology.

[48]  S. Kaler,et al.  ATP7A-related copper transport diseases—emerging concepts and future trends , 2011, Nature Reviews Neurology.

[49]  M. Iskra,et al.  Analysis of serum copper and zinc concentrations in cancer patients , 2007, Biological Trace Element Research.

[50]  J. Froines,et al.  In vitro and in vivo inhibition of lysyl oxidase by aminopropionitriles. , 1992, Journal of toxicology and environmental health.

[51]  J. Balibrea,et al.  Serum and tissue trace metal levels in lung cancer. , 1989, Oncology.